Comments
Zydus Cadila has launched tablet Tenglyn, the generic version of oral anti-diabetic drug Gliptins, in India. Tenglyn, priced at ₹7 a tablet, is almost a sixth of the price at which Gliptins was initially launched in India. The company had earlier launched Lipaglyn in September 2013 for treatment of diabetic dyslipidemia and hyper-triglyceridemia. Shares of Cadila Healthcare, a listed entity of the Zydus Group, will remain in focus.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.